CHEK2 and prostate carcinoma: In comparison, two other genes – SAMHD1 and CHEK2 – showed significant associations in the case-control analysis of prostate cancer risk but demonstrated no association with disease severity, similar to the reported effect of HOXB13 p.Gly84Glu39.